MAPK Pathway Signatures in Oncomine

Pioneering work by Nevins and colleagues demonstrated that microarray-based pathway activation signatures can be used to predict pathway activity in human tumors and suggest strategies for tailoring targeted therapies. We utilized Oncomine Concepts Map to analyze recently published pathway activation signatures for EGFR, ERBB2, B-Raf and Mek.

Open Paper

Download a recording of the recent webinar in wmv format.

Download WMV file (17.3 MB)

Also download a PDF of the slides to follow along and make notes.

Download PDF

Professional Edition

Concepts Edition

Research Premium Edition

Compendia Bioscience, Inc. is dedicated to gathering the world’s high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to ultimately improve the lives of patients.

Compendia Bioscience’s flagship product, Oncomine™, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of success.

Compendia provides product offerings for both Research (non-profit) and Commercial organizations.

19 FEB 2008
COMPENDIA BIOSCIENCE ANNOUNCES SIGNIFICANT REVENUE GROWTH, COMPLETION OF PRODUCT MILESTONE...

Compendia Bioscience, Inc. today announced results of a second productive year, including a renewed and expanding commitment from all major customers and the addition of several “Top 20” oncology drug companies to its customer roster. The new customers and existing customer commitment expansions led to a greater than 300% revenue increase...

Read More